Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ABCL vs MESO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABCL Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–5 Matrix Metrics)

ABCL Overall Winner 6-Pillar Tally: ABCL 3 – 2 MESO (1 Tie) Matrix Metrics: ABCL 5 – 5 MESO

As of Nov 16, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). ABCL carries a Unified Composite Score of 63.3/100 (BUY) at $11.19 (27.6x Forward P/E, -1550.0% operating margin), whereas MESO carries 35.5/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin).

  • Growth vs. Quality Trade-Off: ABCL earns the overall head-to-head edge with a stronger Unified Composite Score (63.3/100 BUY vs. MESO 35.5/100 SELL) and 2.31β · 87% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ABCL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 43.3); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABCL vs MESO
ABCL NASDAQ Head-to-Head Winner
AbCellera Biologics Inc. Common Shares
Pharmaceutical Preparations
$11.19
-2.65% 1D
Market Cap $3.8B
TTM Revenue $66M
Forward P/E 27.6x
Beta / 30D Vol 2.31β · 87% Vol
Unified Composite Score
63.3 / 100 BUY
Tech 57.0 Fund 58.0 Flow 67.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 43.3 · SMA20: $12.04 · SMA50: $12.33
MESO NASDAQ
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
TTM Revenue $120M
Forward P/E N/M
Beta / 30D Vol 1.18β · 78% Vol
Unified Composite Score
35.5 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 38
RSI-14: 38.3 · SMA20: $13.64 · SMA50: $14.22

6-Pillar Scorecard Institutional Category Breakdown (ABCL 3 – 2 MESO)

Columns: Metric · ABCL · MESO
1. Valuation Multiples ABCL
Forward P/E 27.6x N/M
Trailing P/E 27.6x N/M
PEG Ratio N/M N/M
EV / Revenue 56.9x 14.1x
2. Growth & Scale MESO
Revenue Growth (YoY) -76.3% +390.7%
Earnings Growth (YoY) +45.9% +0.0%
TTM Revenue (USD) $66M $120M
Market Cap $3.8B $1.7B
3. Profitability & Quality MESO
Gross Margin N/A 80.0%
Operating Margin -1550.0% -42.6%
Net Profit Margin -248.8% -47.8%
Return on Equity (ROE) -17.3% -9.9%
4. Balance Sheet & Cash Flow ABCL
Cash Generation (TTM) -$33M -$45M EBITDA
Cash Flow Margin -49.6% -37.1% EBITDA Mgn
Net Cash / Leverage $30M Net Cash $4.38 Book/Sh · -9.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABCL
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 80.8% (25th %ile) 76.8% (37th %ile)
Put/Call OI Skew 0.23x (Call-Skewed) Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABCL (5) vs MESO (5)
Institutional Metric ABCL MESO Criterion Row Edge
Market Capitalization
Scale
$3.8B $1.7B Larger Scale ABCL
Trailing P/E Ratio
Valuation
27.6x N/M Lower Multiple ABCL
Forward P/E Ratio
Valuation
27.6x N/M Lower Multiple ABCL
Revenue Growth (YoY)
Growth
-76.3% +390.7% Higher Growth MESO
Operating Margin (TTM)
Profitability
-1550.0% -42.6% Higher Margin MESO
Net Profit Margin
Profitability
-248.8% -47.8% Higher Margin MESO
Return on Equity (ROE)
Capital Efficiency
-17.3% -9.9% Higher ROE MESO
52-Week Range Position
Momentum
69% ($3–$15) 6% ($12–$22) Stronger Trend ABCL
Beta / 30D Volatility
Risk Regime
2.31β · 87% Vol 1.18β · 78% Vol Lower Realized Risk MESO
Unified Institutional Score
Composite Signal
63.3 / 100 (BUY) 35.5 / 100 (SELL) Higher Composite ABCL
Trailing 12M Revenue (USD)
Operating Scale
$66M $120M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 80.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 56.9x EV/Rev N/M PEG · 14.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$33M ($30M Net Cash) -$45M EBITDA ($4.38 Book/Sh · -9.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABCL +0.89 pp
ABCL: -5.21% · MESO: -6.1%
3M Horizon ABCL +25.77 pp
ABCL: +0.58% · MESO: -25.19%
6M Horizon ABCL +183.69 pp
ABCL: +168.87% · MESO: -14.82%
1Y Horizon ABCL +225.4 pp
ABCL: +208.98% · MESO: -16.42%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABCL vs MESO. Trailing 12-month operating profitability (ABCL -1550.0% vs MESO -42.6%) and valuation multiples (ABCL 27.6x vs MESO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ABCL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$66M
Gross MarginN/A
Op. Margin-1550.0%
ROE / Fwd P/E-17.3% · 27.6x
MESO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$120M
Gross Margin80.0%
Op. Margin-42.6%
ROE / Fwd P/E-9.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABCL CONSOLIDATION
34d in phase · OBV NEUTRAL
Current IV 80.8%
IV Percentile 25th %ile
Put/Call OI Skew 0.23x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ABCL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MESO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.8%
IV Percentile 37th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MESO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABCL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.8B market capitalization and -1550.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MESO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -42.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABCL vs MESO Key Questions & Quantitative Answers

As of Nov 16, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). ABCL carries a Unified Composite Score of 63.3/100 (BUY) at $11.19 (27.6x Forward P/E, -1550.0% operating margin), whereas MESO carries 35.5/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin). Growth vs. Quality Trade-Off: ABCL earns the overall head-to-head edge with a stronger Unified Composite Score (63.3/100 BUY vs. MESO 35.5/100 SELL) and 2.31β · 87% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ABCL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 43.3); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MESO leads the Growth & Scale pillar: ABCL posts -76.3% YoY revenue growth and +45.9% YoY earnings growth on $66M TTM revenue (N/A gross margin, -1550.0% operating margin), compared with MESO at +390.7% YoY revenue growth and +0.0% YoY earnings growth on $120M TTM revenue (80.0% gross margin, -42.6% operating margin). On trailing 12-month operating scale, ABCL generates $66M in USD-normalized revenue versus $120M for MESO. In operating R&D and SG&A reinvestment, ABCL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MESO.

ABCL screens cheaper on headline valuation multiples. ABCL trades at 27.6x Forward P/E, 27.6x Trailing P/E, N/M PEG, and 56.9x EV/Revenue (-49.6% FCF margin), whereas MESO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.1x EV/Revenue (-37.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABCL (-17.3% ROE) versus MESO (-9.9% ROE) capital efficiency.

In options market volatility and institutional positioning, ABCL carries 80.8% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.23x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (2.31β · 87% Vol realized risk). By comparison, MESO carries 76.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.